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Propionic acid (PPA) is a ubiquitous short-chain fatty acid which is a fermentation product
of the enteric microbiome and present or added to many foods. While PPA has beneficial
effects, it is also associated with human disorders, including autism spectrum disorders
(ASDs). We previously demonstrated that PPA modulates mitochondrial dysfunction differentially in subsets of lymphoblastoid cell lines (LCLs) derived from patients with ASD.
Specifically, PPA significantly increases mitochondrial function in LCLs that have
mitochondrial dysfunction at baseline [individuals with autistic disorder with atypical
mitochondrial function (AD-A) LCLs] as compared to ASD LCLs with normal mitochondrial
function [individuals with autistic disorder with normal mitochondrial function (AD-N) LCLs]
and control (CNT) LCLs. PPA at 1 mM was found to have a minimal effect on expression
of immune genes in CNT and AD-N LCLs. However, as hypothesized, Panther analysis
demonstrated that 1 mM PPA exposure at 24 or 48 h resulted in significant activation of
the immune system genes in AD-A LCLs. When the effect of PPA on ASD LCLs were
compared to the CNT LCLs, both ASD groups demonstrated immune pathway activation,
although the AD-A LCLs demonstrate a wider activation of immune genes. Ingenuity
Pathway Analysis identified several immune-related pathways as key Canonical Pathways
that were differentially regulated, specifically human leukocyte antigen expression and
immunoglobulin production genes were upregulated. These data demonstrate that the
enteric microbiome metabolite PPA can evoke atypical immune activation in LCLs with
an underlying abnormal metabolic state. As PPA, as well as enteric bacteria which produce PPA, have been implicated in a wide variety of diseases which have components of
immune dysfunction, including ASD, diabetes, obesity, and inflammatory diseases, insight
into this metabolic modulator may have wide applications for both health and disease.
Keywords: mitochondrial disease, autism, propionic acid, short-chain fatty acids, microbiome, inflammation,
epigenetics, histone deacetylase inhibitor

INTRODUCTION
The human microbiome represents a diverse ecosystem of microbes housed in the human body.
Microbial cells outnumber the cells in the human body by a factor of 10 and microbial genes out
number human genes by a factor of over 100 (1–3). There is a particular focus on the enteric (gut)
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microbiota since it represents about 99% of the human microbiome (4). The importance of the enteric microbiome in relation to
human health and disease has been recognized since it appears to
influence the immune system (5), metabolic processes (6), gene
expression (7, 8), the nervous system (9, 10), and behavior (9, 10).
Disruption of the enteric microbiome has been implicated in a
wide range of human diseases including depression and anxiety
(11), gastrointestinal disorders (12), inflammatory airway disease
(13), diabetes (14–16), obesity (17, 18), atopic disease (5), and
neurodegenerative conditions (19). The enteric microbiome may
be particularly important early in life around the time of birth as it
has been linked to early brain development and behavior (9, 10, 20)
and disruption and/or treatments (i.e. early antibiotics) early in life
can influence the development of childhood diseases, particularly
atopic disease (9, 10).
The mechanism in which the enteric microbiome modulates
particular effects on the host is not completely clear, although
several mediators are potential vehicles for such influence. Such
mediators include lipopolysaccharides, peptidoglycans, shortchain fatty acids (SCFAs), neurotransmitters and gaseous molecules (21–23). We are particularly interested in SCFAs because
of their role as both mediators of physiology and mitochondrial
fuels. SCFA are particularly intriguing as they are derived as a
consequence of fermenting carbohydrates and some proteins,
and also present naturally or as an additive in many foods, in
particular wheat and dairy. Thus, dietary variations can have a
larger influence on their production (19, 24, 25). Of the SCFAs,
propionic acid (PPA) has been of key interest because it has several links to autism spectrum disorder (ASD), a disorder which
affects as many as ~2% of children in the United States. What
is intriguing about ASD is that the etiology is largely unknown
but is strongly influenced by both genetic and environmental
factors (26, 27).
The enteric microbiome is a major environmental factor that
may contribute to the etiology of ASD (2, 9, 10, 28). First, several
factors which may have a direct effect on health through disruption
of the microbiome are associated with increased risk of developing ASD, including dietary alteration, environmental exposures
that disrupt enteric microbiome bacteria content and diversity,
being born by C-section delivery which reduces maternal transfer
of enteric and vaginal bacteria, increased antibiotic use which can
destroy key bacteria in the enteric microbiome, formula feeding
and early hospitalization (2, 9, 28). Second, specific bacteria, such
as Clostridia spp., a major SCFA producer, have been repeatedly
reported to be overrepresented in the ASD microbiome (29, 30).
Third, exposure to PPA has been demonstrated in several animal
models to result in the development of ASD-like behaviors and
physiological changes to the brain similar to those found in
ASD are seen in adult rats acutely exposed to PPA (24, 25, 31)
and in juvenile rats systematically exposed to PPA pre- and
postnatally (32–34).
Although the mechanism by which PPA influences host function
is still unclear, data from the animal model of PPA induced ASD demonstrates neuroinflammation and electrophysiological disturbances
as well as disruptions in lipid, mitochondrial and redox metabolism
(24, 25, 31). We have performed a series of studies to demonstrate that
changes in mitochondrial metabolism similar to those found in the
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animal model exposed to PPA are also found in humans. For example, we found that the unique pattern of biomarkers of mitochondrial
dysfunction found in the PPA rodent model was also found in a
subset of children with ASD (28, 35, 36). We also demonstrated that
PPA modulates mitochondrial respiration in lymphoblastoid cell
lines (LCLs) derived from children with ASD differently than LCLs
derived from age and gender matched typically developing control
LCLs (37).
PPA also could induce changes in host physiology through
modulation of the immune system. The animal models of PPA
induced ASD behavior demonstrates neuroinflammation but
inflammatory mediators induced by PPA in human ASD cells has
not been investigated. In this study, we investigate whether PPA
can differentially regulate immune genes using our LCL model of
ASD. We have developed a cell line model of ASD in which LCLs
derived from individuals with autistic disorder (AD) are classified into two groups: those with normal mitochondrial function
(AD-N) and those with atypical mitochondrial function (AD-A)
(38–40). The AD-A LCLs have respiratory rates approximately
twice that of control and AD-N LCLs and are very sensitive to
in vitro increases in reactive oxygen species (ROS) (38–40). We
recently demonstrated that this atypical increase in mitochondrial function characteristic of AD-A LCLs was associated with
more severe repetitive behaviors in the children from which
these LCLs were derived (40). In this way, we believe that the
AD-A LCLs may represent a more severe ASD phenotype. Given
the connection between metabolism and immune system (41),
we hypothesize that the AD-A LCLs will demonstrate a greater
activation of immune genes with PPA exposure as compared to
the control and AD-N LCLs.

MATERIALS AND METHODS
LCLs and Culture Conditions

Lymphoblastoid cell lines were derived from white males
diagnosed with AD chosen from pedigrees with at least other 1
affected male sibling (i.e., multiplex family) [mean (SD) age 7.3
(3.5) years]. These LCLs were obtained from the Autism Genetic
Resource Exchange (Los Angeles, CA, USA) or the National
Institutes of Mental Health (Bethesda, MD, USA) center for collaborative genomic studies on mental disorders. In our previous
studies (37, 39, 40, 42–44), these LCLs where categorized into
two different types of AD LCLs; ones with atypical mitochondrial
respiration (AD-A) and those with normal respiration (AD-N).
These metabolic groupings have been shown to be consistent
and repeatable in our previous studies (37, 39, 40, 42–44). Eight
pairs of AD-N and AD-A LCLs were age and gender matched to
control LCLs. The sample size chosen was based on our previous
studies. Control (CNT) LCLs were derived from healthy white
male donors with no documented behavioral or neurological
disorder and with no first degree relative suffering from any
medical disorder that might involve mitochondrial dysfunction
[mean (SD) age 7.5 (3.3) years]. CNT LCLs were obtained from
Coriell Cell Repository (Camden, NJ, USA). Due to low availability of CNT LCLs which fit our criteria, a single CNT LCL line
was paired with two AD LCL lines in one case (see Table 1). Also
two AD-A LCLs were paired twice with AD-N LCLs. On average,
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Table 1 | Lymphoblastoid cell lines used in this study.
Controls
Cell ID

Source

GM09659
GM17255
GM16007
GM18054
GM11626
GM09642
GM09642
GM09380

Coriell
Coriell
Coriell
Coriell
Coriell
Coriell
Coriell
Coriell

AD-N subgroup

AD-A subgroup

Age (years)

Cell ID

Source

Age (years)

Cell ID

Source

Age (years)

4
6
12
5
13
7
7
6

04C24363
02C10054
05C38988
03C15992
008404
01C08367
04C27439
01C08022

NIMH
NIMH
NIMH
NIMH
AGRE
NIMH
NIMH
NIMH

4
6
12
5
13
7
7
5

1393306
01C08594
1165302
01C08495
1165302
01C08594
02C09713
01C08495

AGRE
NIMH
AGRE
NIMH
AGRE
NIMH
NIMH
NIMH

3
7
13
4
13
7
7
4

Three types of cell lines were used with two types of autistic disorder (AD) cell lines, characterized in our previous studies, and one type of control cell line.

cells were studied at passage 12, with a maximum passage of 15.
Genomic stability is very high at this low passage number (45,
46). Cells were maintained in RPMI 1640 culture medium with
15% FBS and 1% penicillin/streptomycin (Invitrogen, Grand
Island, NY, USA) in a humidified incubator at 37°C with 5% CO2.

Table S1 in Supplementary Material demonstrates the number of
genes up- and downregulated more than 2.0-fold for each LCL
type.
The CNT LCLs demonstrated no upregulation or downregulation of known genes with 24 h PPA exposure and only one gene
upregulated and downregulated with 48 h PPA exposure. Only
the downregulated gene was associated with immune function.
Panther analysis demonstrated no overrepresentation of immune
genes associated with PPA exposure in CNT LCLs.
Exposure of AD-N LCLs to PPA for 24 h demonstrated no
upregulated genes and downregulation of several immune genes
including two major histocompatibility complex genes. Exposure
of AD-N LCLs to PPA for 48 h demonstrated upregulation of two
microRNA genes not known to be involved in immune function
and downregulation of the gene for complement C4B. Panther
analysis demonstrated overrepresentation of genes associated
with major histocompatibility complex antigen with 24 h PPA
exposure in AD-N LCLs (see Table 2).
Exposure of AD-A LCLs to PPA for 24 or 48 h demonstrated
upregulation of several genes related to immune function,
particularly several genes associated with immunoglobulin production and one gene related to activation of proinflammatory
caspases. Downregulation of the gene for complement C4B was
found for 24 h exposure and no genes were downregulated for
48 h exposure. Panther analysis demonstrated overrepresentation of many immune processes and proteins as result of PPA
exposure to AD-A LCLs for 24 and 48 h, demonstrating that
PPA did significantly activate immune processes for AD-A LCLs
(Table 2).

PPA Exposure

Each group of LCLs were cultured with PPA 1 mM for 24 or
48 h or left untreated (0 mM). This concentration was selected
because it provided optimal metabolic activation in our previous
studies (37). The sodium propionate was buffered with sodium
bicarbonate in the culture medium to prevent changes in pH
which could cause changes in influx of PPA (47). As PPA is mostly
disassociated at physiological pH, the effects of the PPA treatment
are most likely a combination of both PPA and propionate.

Expression Studies

Total RNA samples from each LCL group were pooled together
and after DNase treatment and purified using RNeasy Mini
Kit (Qiagen Sciences, MD, USA) as described in our previous
studies (48). The cDNA synthesis and microarray analyses were
performed at Keck Affymetrix GeneChip Resource at Yale, New
Haven, CT, USA (NIH Neuroscience Microarray Consortium) as
previously described (48).

Analytic Approach

Analysis of variance was conducted between the exposure conditions and different cell types. Genes showing expression of at
least ≥2.0-fold were exported for functional annotation to several
pathway analysis packages including Ingenuity Pathway Analysis
(IPA) and Panther software. For the initial comparison of the
effect of PPA for each exposure time on a particular LCL type,
the statistical significance of the comparison was not considered
as there was only an N of 1 for each example. When the ASD
LCL types were compared to controls, the two PPA exposure
times were combined and the genes selected not only showed a
difference in expression of at least ≥2.0-fold but also a p < 0.05.

Comparison of PPA Effect on ASD LCLs
as Compared to Control LCLs

To better understand how PPA exposure affects ASD LCLs differently than control LCLs, gene expression was compared between
CNT LCLs and each ASD LCL group independently. Both the
24- and 48-h PPA exposure data was combined since the previous analysis demonstrated little difference between the changes
in gene expression with these two different exposure durations.
Table S2 in Supplementary Material outlines the genes that were
upregulated or downregulated with PPA exposure for each ASD
LCL group as compared to CNT LCLs. Table 3 demonstrates the
biological processes identified by the differential gene expression
for AD-N and AD-A LCLs as compared to CNT LCLs. The major
processes identified are also represented in Figure 1. Biological

RESULTS
The Effect of PPA on Gene Expression
for Each LCL Type

The change in gene expression resulting from 1 mM exposure to
PPA for 24 and 48 h was determined for each LCL type separately.
Frontiers in Immunology | www.frontiersin.org
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Table 3 | Biological processes panther overrepresentation analysis of genes
differentially expressed in autism cell lines as compared to control cell lines.

Table 2 | Panther overrepresentation analysis of genes significantly upregulated
and downregulated with 24 and 48 h PPA exposure.
# of genes
AD-N downregulated 24 h
Protein class
Major histocompatibility
complex antigen
AD-A upregulated 24 and 48 h
Biological process
Immune response
Response to stimulus
Cellular component
Immunoglobulin complex
Extracellular space
Extracellular region
Protein class
Immunoglobulin
Defense-immune protein
Molecular function
Antigen binding
Biological processes
Immunoglobulin production
Production of mediator of
immune response
Immune response

Enrichment

p-Value

2

91.31

<0.05

6
7

20.87
5.83

<0.0001
<0.01

2
6
6

54.91
26.32
19.08

<0.05
<0.0001
<0.0001

4
4

99.3
19.78

<0.0001
<0.01

4

44.66

<0.01

4
4

79.78
69.14

<0.01
<0.01

7

9.83

<0.01

AD-N LCLs
Down

Up

Down

8
8
22

0
0
0

9
9
20

0
0
0

Phagocytosis (recognition)
Phagocytosis

0
0

0
0

5
9

5
6

Phagocytosis (engulfment)
Plasma membrane invagination
Membrane invagination

0
0
0

0
0
0

5
5
5

5
5
5

B cell receptor signaling pathway
Antigen receptor-mediated signaling
Activating cell surface receptor
Regulating cell surface receptor
Response-regulating signaling
Response-activating signaling
Activation of immune response
Regulation of response

5
8
10
10
10
10
10
12

0
0
0
0
0
0
0
0

6
8
12
12
12
12
12
13

6
8
10
10
10
10
10
10

Leukocyte migration
Cell migration
Cell motility
Locomotion
Subcellular component movement
Localization of cell

8
13
13
13
14
13

0
0
0
0
0
0

0
0
0
0
0
0

0
0
0
0
0
0

Adaptive immune response
Immune response

9
19

0
6

13
20

0
0

Complement activation, classical pathway
Complement activation
Protein activation cascade
Humoral immune response
Mediated by immunoglobulin
Immunoglobulin mediated
B cell-mediated immunity
Receptor recombination
Lymphocyte mediated
Leukocyte mediated

0
0
0
0
0
0
0
0
0
0

0
0
0
0
0
0
0
0
0
0

8
8
9
9
9
9
9
9
9
12

6
6
6
6
6
6
6
7
8
8

Regulation of B cell activation

0

0

6

6

Numbers represent number of genes associated with the identified biological process.

ASD demonstrates neuroinflammation and immune activation,
including increased GFAP immunoreactivity in the hippocampus, increased activation of microglia, and increased interleukin
(IL)-6 (24, 25, 31). We further hypothesized that the AD-A LCLs
would have a greater enhancement of immune pathways since
this is a more severe ASD phenotype and since optimal mitochondrial function is required for appropriate immune function
and response (41).
Exposure to PPA for either 24 or 48 h resulted in upregulation
in genes associated with immune system activation in AD-A
LCLs, particularly genes involved in immunoglobulin production. This effect was not seen in CNT or AD-N LCLs. In fact,
there was a decrease in major histocompatibility complex antigen
genes in AD-N LCLs exposed to PPA for 24 h. We then compared the effect of PPA on ASD LCLs as compared to the effect
of PPA on CNT LCLs. We found that both the AD-N and AD-A
LCLs demonstrated changes in gene expression as compared to
the control LCLs with a significant change in genes related to
immune pathways almost exclusively. Although the AD-N LCLs

DISCUSSION
In this study, we examined the effect of PPA, a SCFA produced
by enteric bacteria that are overrepresented in the ASD gut, on
transformed B cells (LCLs) derived from children with ASD as
well as controls. We examined two types of LCLs derived from
children with ASD, those with mitochondrial dysfunction (ADA) and those found to have mitochondrial function similar to
controls (AD-N). We hypothesized that PPA would activate
immune pathways in ASD LCLs since the PPA animal model of
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Up
Immunoglobulin production
Mediator of immune response
Immune system process

process was the only Panther analysis used as it was the most
robust for representing the difference in pathway activation.
This analysis suggests that both the AD-N and AD-A LCLs
demonstrate change in immune genes as compared to CNT LCLs.
Both AD-A and AD-N LCLs demonstrate an upregulation in
genes associated with immunoglobulin production and adaptive
immune responses without any downregulation in genes involved
in these processes. AD-A LCLs demonstrate both upregulation
and downregulation of genes involved in a wider variety of
immune responses as compared to AD-N LCLs, including
phagocytosis, complement system activation, B cell regulation,
and B cell receptors. This suggests that AD-A LCLs may have a
wider network of immune genes activated as compared to AD-N
LCLs as well as CNT LCLs.
Table 4 represents the top canonical pathways (p < 0.01)
identified by IPA for the comparison between the AD-A and
CNT LCLs. As we see, many of these processes are involved in
immune activation and immune disorders. IPA also identified
the top upstream regulators as RUNX3, ONECUT1, SNAI2,
STAT5A, and TCF7. Interestingly, as will be discussed below,
these genes are regulatory of both developmental and immune
processes.

AD-A LCLs
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development through lineage specification (52). Interestingly,
RUNX3 is involved in the TNF-beta signaling cascade (53),
a cytokine whose dysregulation has been correlated with ASD
severity (51). RUNX3 appears to have an important role in the
development of proprioceptive afferent neurons in mice, resulting in ataxia (54), a neurological finding that is not uncommon in
ASD. Other genes identified are related to B cell function. SNAI2
is an evolutionarily conserved zinc finger transcription factor
which plays an important role in prenatal fetal development, most
notably the development of neural crest-derived cells and adipocytes (55). SNAI2 is also involved in regulation of B cells and can
promote the aberrant survival and malignant transformation of
mammalian pro-B cells otherwise slated for apoptotic death (56)
and has antiapoptotic effects (57).
In conclusion, ASD is being recognized as having a very
strong immune component to its etiology (58). Several models
of ASD demonstrate immune dysregulation, including prenatal
exposure to immune challenges (59, 60). In fact two animal
models have been developed to parallel prenatal exposure to
autoantibodies (61), including fetal brain antibodies (62) and
antibodies to the folate transporter (63, 64). The microbiome is
being recognized as important in the etiology of neurodevelopmental disorders (9, 10), potentially through modulation of the
immune system (65) through enteric metabolites (65) including
SCFAs like PPA (24, 25, 31). It is important to note the effects
of SCFA on gene expression and inflammation are complex, and
include histone deacetylase activity, activation of free fatty acid
G-coupled receptor and mitochondrial inflammatory signaling cascades, which may or may not be mutually reinforcing.
Furthermore, we do not yet know if the effects found in our LCL
model also occur in patients, as many effects of SCFA, in particular PPA and butyrate, are dose and tissue dependent, and have
different effects at key developmental time periods (9, 10, 24,
31, 48, 66, 67). Nonetheless, this study provides insight into the
mechanism in which the microbiome may influence the immune
system to result in disease and demonstrates the predisposition
of certain cells to be sensitive to microbiome metabolites. It also
may lead to further reevaluation of the widespread use of PPA
in agriculture and the food industry (24, 31). Certainly, further
research is needed in this area to better define the role of the
microbiome and microbial metabolites in immune modulation
and disease.

Figure 1 | Biological processes associated with an increase or decrease in
gene expression resulting from propionic acid exposure to autism cell lines as
compared to control cell lines.

Table 4 | Top canonical pathways identified using Ingenuity Pathway
Analysis (IPA).
B cell development
T helper cell differentiation
Primary immunodeficiency signaling
Graft-versus-host disease signaling
Calcium-induced T lymphocyte apoptosis
IL-4 signaling
Altered T cell and B cell signaling in rheumatoid arthritis
Antigen presentation pathway

demonstrated activation of immune pathways, the AD-A LCLs
demonstrated a wider range of genes and processes involved in
immune pathways. In addition, IPA analysis of AD-A LCL gene
expression changes identified canonical pathways almost exclusively related to immune function.
Several of the genes identified by the IPA analysis are involved
in regulation of the immune system and may be linked to
ASD. Several genes are linked to regulation of T cells. TCF7 is
a T lymphocyte-specific enhancer of the CD3-Epsilon T cell
antigen receptor complex. Interestingly TCF7 expression may
be regulated by beta-catenin (49). This is intriguing since betacatenin has been shown to be dysregulated in an animal model of
ASD (50). STAT5 is induced in response to T cell activation with
cytokines, most notably IL-2, and is believed to be involved in
the effect of IL-2 in the immune response and may be involved in
the suppression of IL-3 production. This is interesting as IL-2 is
produced by neurons and astrocytes, is important in brain development and normal brain physiology and has been implicated in
neurodegenerative disease, cognitive dysfunction and has been
linked to ASD (51). RUNX3 is also important in immune system
function as well as neuronal development. RUNX3 is essential
during thymopoiesis where it modulates the development of
CD8 T cells, thus having an important role in immune system

Frontiers in Immunology | www.frontiersin.org
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